Sandoz Canada receives Health Canada approval for Erelzi (etanercept) in the Treatment of Psoriatic Arthritis (PsA) in Adult Patients
- Erelzi is the only etanercept biosimilar to be indicated for reducing the signs and symptoms of psoriatic arthritis (PsA) in adult patients.
- Up to 90,000 Canadians have or may have PsA, a disease which affects both men and women in equal numbers.[1]
[1] The Arthritis Society: https://arthritis.ca/getmedia/5ec4341d-fe11-49d5-ad05-c79928fb10fa/what-is-psoriatic-arthritis-infographic.pdf. Accessed on January 9, 2019. [2] Erelzi? (etanercept) is not indicated for the treatment of plaque psoriasis at this time. [3] The Arthritis Society: https://www.arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis. Accessed on January 9, 2019. [4] Fact Sheet: Biosimilars: Government of Canada: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/fact-sheet-biosimilars.html. Accessed on January 9, 2019. [5] Potential Savings from Biosimilars in Canada: Government of Canada: http://www.pmprb-cepmb.gc.ca/view.asp?ccid=1304. Accessed on January 9, 2019. [6] Sandoz Canada: https://www.sandoz.ca/en/our-work/biopharmaceuticals/erelzi. Accessed on January 9, 2019.
Related Articles
More articles issued by?Sandoz Canada
More articles related to:
Company Announcement
Profile
Sandoz Canada